Abstract
More than 99% of currently approved clinical drugs are organic compounds. In contrast, the percentage of metal-containing drugs (metallodrugs) is very low. In cancer chemotherapy, however, platinum coordination compounds represented by cisplatin and derivatives thereof are essential anticancer agents with proven effects against a variety of tumors. Because of the proven clinical applications of these platinum-based drugs, the number of research initiatives to identify other metallodrugs that can be used for cancer therapy has increased considerably in the field of inorganic biochemistry. Anticancer platinum compounds continue to be designed and synthesized through several different approaches in order to improve the therapeutic effects and to overcome the disadvantages of current platinum-based drugs. The use of transition metal compounds other than platinum has also attracted attention. Gold coordination complexes, for instance, demonstrate outstanding cytotoxic properties, and certain ruthenium complexes possess a strong ability to inhibit metastases of solid invasive tumors. In this review, the potential of anticancer metallodrugs is described and representative examples from the most recent families of Pt-, Ru-, and Au-based compounds are discussed with respect to their possible modes of action and most probable biomolecular targets.
Keywords: Metallodrugs, cancer, nucleic acids, protein targets, clinical drugs, organic compounds, cancer chemotherapy, inorganic biochemistry, ruthenium complexes possess, biomolecular targets, platinum electrodes, high therapeutic efficacy, antitumor-active Pt(II) complexes, Cisplatin-resistant cells
Current Topics in Medicinal Chemistry
Title: Next-Generation Anticancer Metallodrugs
Volume: 12 Issue: 3
Author(s): Seiji Komeda and Angela Casini
Affiliation:
Keywords: Metallodrugs, cancer, nucleic acids, protein targets, clinical drugs, organic compounds, cancer chemotherapy, inorganic biochemistry, ruthenium complexes possess, biomolecular targets, platinum electrodes, high therapeutic efficacy, antitumor-active Pt(II) complexes, Cisplatin-resistant cells
Abstract: More than 99% of currently approved clinical drugs are organic compounds. In contrast, the percentage of metal-containing drugs (metallodrugs) is very low. In cancer chemotherapy, however, platinum coordination compounds represented by cisplatin and derivatives thereof are essential anticancer agents with proven effects against a variety of tumors. Because of the proven clinical applications of these platinum-based drugs, the number of research initiatives to identify other metallodrugs that can be used for cancer therapy has increased considerably in the field of inorganic biochemistry. Anticancer platinum compounds continue to be designed and synthesized through several different approaches in order to improve the therapeutic effects and to overcome the disadvantages of current platinum-based drugs. The use of transition metal compounds other than platinum has also attracted attention. Gold coordination complexes, for instance, demonstrate outstanding cytotoxic properties, and certain ruthenium complexes possess a strong ability to inhibit metastases of solid invasive tumors. In this review, the potential of anticancer metallodrugs is described and representative examples from the most recent families of Pt-, Ru-, and Au-based compounds are discussed with respect to their possible modes of action and most probable biomolecular targets.
Export Options
About this article
Cite this article as:
Komeda Seiji and Casini Angela, Next-Generation Anticancer Metallodrugs, Current Topics in Medicinal Chemistry 2012; 12 (3) . https://dx.doi.org/10.2174/156802612799078964
DOI https://dx.doi.org/10.2174/156802612799078964 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the AKT Pathway in Glioblastoma
Current Pharmaceutical Design Hematopoietic Stem Cells: Transcriptional Regulation, Ex Vivo Expansion and Clinical Application
Current Molecular Medicine Oral Precancerous Lesions Show Increased Levels of Glutathione Compared to Cancerous Tissue
Current Nutrition & Food Science Current Status in Iron Chelation in Hemoglobinopathies
Current Molecular Medicine Editorial [Hot Topic: The Pineal Hormone Melatonin in Health and Disease (Guest Editors: Charanjit Kaur)]
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Identification of Novel Sesamol Dimers with Unusual Methylenedioxy Ring-Opening Skeleton and Evaluation of Their Antioxidant and Cytotoxic Activities
Current Organic Synthesis Regulation of Epithelial-Mesenchymal Transition by E3 Ubiquitin Ligases and Deubiquitinase in Cancer
Current Cancer Drug Targets Discovery of BRM Targeted Therapies: Novel Reactivation of an Anticancer Gene
Letters in Drug Design & Discovery Development of Doxorubicin Quantification by Reductive Amination
Current Analytical Chemistry Meet Our Editorial Board Member
Drug Delivery Letters Fibroblast Growth Factor Receptor Inhibitors
Current Pharmaceutical Design Toxicity of 11 Metal Oxide Nanoparticles to Three Mammalian Cell Types <i>In Vitro</i>
Current Topics in Medicinal Chemistry Anticancer Effects of Ginsenoside Rh2: A Systematic Review
Current Molecular Pharmacology Animal Models of Atherosclerosis Progression: Current Concepts
Current Drug Targets - Cardiovascular & Hematological Disorders N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Cancer: A Problem of Developmental Biology; Scientific Evidence for Reprogramming and Differentiation Therapy
Current Drug Targets Antioxidant, Pro-Oxidant and Other Biological Activities of Sesquiterpenes
Current Topics in Medicinal Chemistry Clinical Experience with Antiangiogenic Therapy in Leukemia
Current Cancer Drug Targets Effective Inhibition of Mitochondrial Metabolism by Cryptotanshinone in MDA-MB231 cells: A Proteomic Analysis
Current Proteomics Resveratrol-Mediated Reversal of Tumor Multi-Drug Resistance
Current Drug Metabolism